Peptide T (TFA)

• UNSPSC Description:

  Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.

• Target Antigen:

  HIV

• Type:

  Peptides

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/Peptide_T_TFA.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(O)C(F)(F)F.OC(C=C1)=CC=C1C[C@@H](C(N[C@H](C(O)=O)[C@H](O)C)=O)NC([C@H](CC(N)=O)NC([C@H](C(O)C)NC([C@H]([C@H](O)C)NC([C@H]([C@H](O)C)NC([C@H](CO)NC([C@@H](N)C)=O)=O)=O)=O)=O)=O

• Molecular Weight:

  971.89

• References & Citations:

  [1]Ruff MR, et al. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment. Lancet. 1987 Sep 26;2(8561):751.|[2]Ruff MR, et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 2001 Oct;52(1):63-75.|[3]Raychaudhuri SP, et al. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol. 1999 Sep;21(9):609-15.|[4]Sáez-Torres I, et al. Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol. 2000 Jul;121(1):151-6.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1610056-01-3